29 January 2021

Novavax announced that its protein-based Covid-19 vaccine candidate NVX-CoV2373 has met its primary endpoint and achieved 89.3% efficacy in a Phase III clinical trial carried out in the UK. The company collaborated with the UK’s Vaccine Taskforce for the study. Novavax also published successful results from its Phase IIb study in South Africa.

RedHill Biopharma announced an agreement with Cosmo Pharmaceuticals to expand the manufacturing capacity for the former’s Covid-19 drug Opaganib to help address emerging viral strains following potential future global emergency use authorisations. The orally administered inhibitor achieve top results in its Phase II study, and is currently being evaluated in a Phase II/III trial.

Kintor Pharmaceutical announced that its clinical trial of Proxalutamide for treating hospitalised Covid-19 patients has been approved by the Institutional Review Board of Brazil. The trial has been approved for further accelerated review and the Brazilian government has agreed to provide medical resources to enable patient recruitment to begin at the weekend.

Speciality vaccine company Valneva has begun the production of its inactivated, adjuvanted Covid-19 vaccine candidate alongside its ongoing clinical studies. The company stated that it has begun production to optimise potential deliveries of the vaccine in the months ahead. Recruitment for a Phase I/II clinical study is now complete and will report initial results in April 2021.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.